CME/CE
Episodes 65-80 of 99
P. Gabriel Steg, MD
Lale Tokgözoğlu, MD
- MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program creditKausik Ray, MBChB, MD, MPhil
- MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program creditErin D. Michos, MD, MHS, FACC, FAHA, FASE
Fabrice Martens, MD, PhD, FESC
Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Fabrice Martens, MD, PhD, FESC
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Roxana Mehran, MD
- MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program creditJohn Kastelein, MD, PhD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Carolyn Ho, MD
Antonis Pantazis, MD
Pablo García-Pavía, MD, PhD
Carolyn Ho, MD
Antonis Pantazis, MD
Pablo García-Pavía, MD, PhD
- MinuteCE®
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
1.00 credit 3 episodesRichard Hobbs, MD
Lale Tokgözoğlu, MD
Victor Aboyans, MD, PhD
- MinuteCE®
Integrating icosapent ethyl in preventive strategies: Practical guidance
1.00 program creditVictor Aboyans, MD, PhD
